Dikla Akselbrad
Vermögen: 4 801 $ am 31.08.2026
Vermögen: 4 801 $ am 31.08.2026
Dikla Czaczkes Akselbrad currently works at PolyPid Ltd., as Chief Executive Officer & Director from 2022.
Ms. Akselbrad also formerly worked at Compugen Ltd., as Chief Financial Officer from 2008 to 2014, Ernst & Young (Israel) Ltd., as Audit Manager from 1997 to 2000, and Packet Technologies Ltd., as Chief Financial Officer from 2000 to 2002.
Ms. Akselbrad received her undergraduate degree and Masters Business Admin degree from Tel-Aviv University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
POLYPID LTD. 0,01 % | 15.07.2026 | 934 ( 0,01 % ) | 4 801 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| POLYPID LTD. | Vorstandsvorsitzender | 01.07.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
| COMPUGEN LTD. | Finanzdirektor/CFO | 01.05.2014 |
Packet Technologies Ltd. | Finanzdirektor/CFO | 01.01.2002 |
Ernst & Young (Israel) Ltd.
Ernst & Young (Israel) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Comptroller/Controller/Auditor | 01.01.2000 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Compugen Ltd.
Compugen Ltd. BiotechnologyHealth Technology Discovers and researches drug & diagnostics | Health Technology |
Tel-Aviv University
Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ernst & Young (Israel) Ltd.
Ernst & Young (Israel) Ltd. Miscellaneous Commercial ServicesCommercial Services Provides accounting services | Commercial Services |
PolyPid Ltd.
PolyPid Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage specialty pharmaceutical company that is engaged in developing of product candidates based on polymer-lipid encapsulation matrix technology | Health Technology |
Packet Technologies Ltd. |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen